Review
Published on 17 Jan 2025
The role of multiomics in revealing the mechanism of skin repair and regeneration
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1497988
- 1,775 views
Type at least 3 characters
2,865 articles
Review
Published on 17 Jan 2025
Plant protein-derived anti-breast cancer peptides: sources, therapeutic approaches, mechanisms, and nanoparticle design
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1468977
- 1,759 views
- 2 citations
Case Report
Published on 15 Jan 2025
Case report: Tocilizumab for hypersensitivity reaction after oxaliplatin in a patient with NK/T-cell lymphoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1471038
- 1,057 views
- 1 citation
Original Research
Published on 15 Jan 2025
Parishin B blocking TRIB3-AKT1 interaction inhibits breast cancer lung metastasis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1517708
- 1,453 views
Original Research
Published on 15 Jan 2025
Oxyresveratrol as a novel ferroptosis inducer exhibits anticancer activity against breast cancer via the EGFR/PI3K/AKT/GPX4 signalling axis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1527286
- 1,837 views
- 1 citation
Original Research
Published on 15 Jan 2025
Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1510851
- 2,098 views
- 1 citation
Review
Published on 15 Jan 2025
The mechanism underlying metastasis in triple-negative breast cancer: focusing on the interplay between ferroptosis, epithelial-mesenchymal transition, and non-coding RNAs
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1437022
- 2,082 views
Original Research
Published on 14 Jan 2025
DNA methylation inhibitors adverse reaction characteristic analysis: an analysis based on the European spontaneous adverse event reporting system
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1527903
- 992 views
Review
Published on 14 Jan 2025
Hydroxysafflor yellow A: a natural pigment with potential anticancer therapeutic effect
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1495393
- 1,697 views
- 3 citations
Original Research
Published on 13 Jan 2025
Integration of histone modification-based risk signature with drug sensitivity analysis reveals novel therapeutic strategies for lower-grade glioma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1523779
- 1,574 views
Original Research
Published on 13 Jan 2025
CSNK1E is involved in TGF-β1 induced epithelial mesenchymal transformationas and related to melanoma immune heterogeneity
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1501849
- 1,141 views
Review
Published on 10 Jan 2025
Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1493188
- 2,581 views
- 1 citation
Original Research
Published on 09 Jan 2025
Computer-assisted discovery of natural inhibitors for platelet-derived growth factor alpha as novel therapeutics for thyroid cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1512864
- 2,192 views
- 1 citation
Brief Research Report
Published on 09 Jan 2025
Urolithin A increases the natural killer activity of PBMCs in patients with prostate cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1503317
- 2,083 views
- 3 citations
Original Research
Published on 09 Jan 2025
Gut microbiota derived metabolite trimethylamine N-oxide influences prostate cancer progression via the p38/HMOX1 pathway
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1526051
- 1,904 views
- 1 citation
Review
Published on 09 Jan 2025
Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1463520
- 1,878 views